Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

References

• MorenoSLopez AldeguerJArribasJRThe future of antiretroviral therapy: challenges and needsJ Antimicrob Chemother20106582783520228080
   PubMed Web of Science ®Google Scholar
• NachegaJBMugaveroMJZeierMVitoriaMGallantJETreatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costsPatient Prefer Adherence2011535736721845035
   PubMed Web of Science ®Google Scholar
• BangsbergDRHechtFMCharleboisEDAdherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent populationAIDS20001435736610770537
   PubMed Web of Science ®Google Scholar
• BartlettJAFathMJDemasiRAn updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS2006202051206417053351
   PubMed Web of Science ®Google Scholar
• NachegaJBHislopMDowdyDWChaissonRERegensbergLMaartensGAdherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomesAnn Intern Med200714656457317438315
   PubMed Web of Science ®Google Scholar
• ParientiJJBangsbergDRVerdonRGardnerEMBetter adherence with once-daily antiretroviral regimens: a meta-analysisClin Infect Dis20094848448819140758
   PubMed Web of Science ®Google Scholar
• PulidoFRiberaEMorenoSOnce-daily antiretroviral therapy: Spanish Consensus StatementJ Antimicrob Chemother20055680881816150862
   PubMed Web of Science ®Google Scholar
• WoodEHoggRSYipBHarriganPRO’ShaughnessyMVMontanerJSEffect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/LAnn Intern Med200313981081614623618
   PubMed Web of Science ®Google Scholar
• NegredoEMoltoJMunoz-MorenoJASafety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approachAntivir Ther2004933534215259896
   PubMed Web of Science ®Google Scholar
• BarriosANegredoEDomingoPSimplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trialAntivir Ther20051082583216312178
   PubMed Web of Science ®Google Scholar
• RuanePLangJDeJesusEPilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infectionHIV Clin Trials2006722923617162316
   PubMed Web of Science ®Google Scholar
• BangsbergDRRaglandKMonkADeeksSGA single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed peopleAIDS201024182835284021045636
   PubMed Web of Science ®Google Scholar
• MachaSYongCLDarringtonTIn vitro-in vivo correlation for nevirapine extended release tabletsBiopharm Drug Dispos20093054255019876936
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdfAccessed September 1, 2011
   Google Scholar
• van LethFPhanuphakPRuxrungthamKComparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyLancet20043631253126315094269
   PubMed Web of Science ®Google Scholar
• MaitlandDJacksonAOsorioJMandaliaSGazzardBGMoyleGJSwitching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyHIV Med2008966767218631255
   PubMed Web of Science ®Google Scholar
• RiddlerSAHaubrichRDiRienzoAGClass-sparing regimens for initial treatment of HIV-1 infectionN Engl J Med20083582095210618480202
   PubMed Web of Science ®Google Scholar
• SquiresKLazzarinAGatellJMComparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIVJ Acquir Immune Defic Syndr2004361011101915247553
   PubMed Web of Science ®Google Scholar
• BoyleBAJayaweeraDWittMDGrimmKMaaJFSeekinsDWRandomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppressionHIV Clin Trials2008916417618547903
   PubMed Web of Science ®Google Scholar
• KleinRStrubleKApproval of Viramune XR (nevirapine) 400 mg extended release tabletFDA announcement of Viramune XR approval Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm248800.htmAccessed September 12, 2011
   Google Scholar
• GatheJAndrade-VillanuevaJSantiagoSEfficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsAntivir Ther20111675976921817198
   PubMed Web of Science ®Google Scholar
• AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
   PubMed Web of Science ®Google Scholar
• DeJesusEPozniakAGallantJImprovement in fasting lipids but minimal recovery of limb fat were seen 96 weeks after switching from lamivudine/zidovudine plus efavirenz to fixed-dose efavirenz/emtricitabine/tenofovir DF in HIV-infected patientsPaper presented at the 49th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 12–15, 2009San Francisco, CA
   Google Scholar
• EronJRockstrohJAndrade-VillanuevaJMadrugaJQDMRK, a phase III study of the safety and efficacy of once-daily vs twice-daily RAL in combination therapy for treatment-naive HIV-infected patientsPaper presented at the 18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 3, 2011Boston, MA
   Google Scholar
• JayaweeraDDejesusENguyenKLGrimmKButcherDSeekinsDWVirologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-naive HIV-1-infected patients over 96 weeksHIV Clin Trials20091037538420133268
   PubMed Web of Science ®Google Scholar
• JohnsonMAGatheJCJrPodzamczerDA once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenJ Acquir Immune Defic Syndr20064315316016951643
   PubMed Web of Science ®Google Scholar
• ZajdenvergRPodsadeckiTJBadal-FaesenSSimilar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeksJ Acquir Immune Defic Syndr20115414315120134330
   PubMed Web of Science ®Google Scholar
• ZeldinRKPetruschkeRAPharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJ Antimicrob Chemother2004534914657084
   PubMed Web of Science ®Google Scholar
• ClotetBOnce-daily dosing of nevirapine in HAARTJ Antimicrob Chemother200861131618006524
   PubMed Web of Science ®Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS2009231679168819487905
   PubMed Web of Science ®Google Scholar
• MillsEJNachegaJBBangsbergDRAdherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitatorsPLoS Med20063e43817121449
   PubMed Web of Science ®Google Scholar
• UchinoBNSocial support and health: a review of physiological processes potentially underlying links to disease outcomesJ Behav Med20062937738716758315
   PubMed Web of Science ®Google Scholar
• NachegaJBHislopMNguyenHAntiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern AfricaJ Acquir Immune Defic Syndr200951657119282780
   PubMed Web of Science ®Google Scholar
• PetersenMLWangYvan der LaanMJGuzmanDRileyEBangsbergDRPillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysisClin Infect Dis20074590891517806060
   PubMed Web of Science ®Google Scholar
• SimoniJMPearsonCRPantaloneDWMarksGCrepazNEfficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trialsJ Acquir Immune Defic Syndr200643Suppl 1S233517133201
   PubMed Web of Science ®Google Scholar
• GrantRMLamaJRAndersonPLPreexposure chemoprophylaxis for HIV prevention in men who have sex with menN Engl J Med20103632587259921091279
   PubMed Web of Science ®Google Scholar
• Abdool KarimQAbdool KarimSSFrohlichJAEffectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenScience20103291168117420643915
   PubMed Web of Science ®Google Scholar
• BishaiDColcheroADurackDTThe cost effectiveness of antiretroviral treatment strategies in resource-limited settingsAIDS2007211333134017545710
   PubMed Web of Science ®Google Scholar
• NachegaJBLeisegangRBishaiDAssociation of antiretroviral therapy adherence and health care costsAnn Intern Med2010152182520048268
   PubMed Web of Science ®Google Scholar
• PurdumAGJohnsonKAGlobeDRComparing total health care costs and treatment patterns of HIV patients in a managed care settingAIDS Care20041676778015370064
   PubMed Web of Science ®Google Scholar
• WrightDRodriguezAGodofskyEEfficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patientsHIV Clin Trials200892738218474492
   PubMed Web of Science ®Google Scholar